Galapagos and Asinex have initiated an integrated drug discovery collaboration in bone and joint diseases
Galapagos and Asinex have initiated an integrated drug discovery collaboration in bone and joint diseases.
The collaboration will result in a set of optimised leads for Galapagos's validated bone and joint disease drug targets.
In the first phase of the collaboration, Galapagos biologists will work closely with Asinex's medicinal chemists, using Asinex's computational chemistry expertise and proprietary chemical compound libraries to generate new leads for Galapagos's proprietary targets.
The second phase will consist of the design and optimisation of the lead structures.
Asinex's aim is to provide Galapagos with a patentable candidate drug series.
"Galapagos has identified a set of proteins that play a pivotal role in bone formation through its functional screening platform." said Graham Dixon, Galapagos's chief scientific officer "Asinex's expertise in computational and medicinal chemistry complements Galapagos's strong disease biology expertise and it will extend our small molecule drug candidate portfolio in our core disease areas.
"Therefore, this collaboration will ensure maximum chances of success for Galapagos' drug discovery programsme".
Dmitry Genis, Asinex's CEO, stated: "We are delighted that Galapagos has chosen Asinex in order to initiate its drug discovery programmes.
"We believe that Asinex's integrated drug discovery services are very hard to surpass.
"We are fully committed to providing Galapagos with a high value set of lead compounds and to develop a successful and long-term relationship."
